GLP-1 Medications and Fertility: What You Need to Know Before, During, and After Pregnancy

Can GLP-1 Medications Improve Fertility?

Weight loss of 5-10% of body weight can restore spontaneous ovulation in women whose cycles have been suppressed by obesity or polycystic ovary syndrome (PCOS). Because semaglutide and tirzepatide produce substantially greater weight reduction than lifestyle intervention alone, they can indirectly improve fertility before they need to be stopped for conception.

Adipose tissue generates excess estrone and suppresses the hypothalamic-pituitary-ovarian axis. Reducing fat mass lowers circulating androgens, reduces insulin resistance, and allows luteinizing hormone (LH) pulsatility to normalize. A 2023 randomized controlled trial (N=84) published in the Journal of Clinical Endocrinology and Metabolism found that semaglutide 1.0 mg weekly restored regular menstrual cycles in 62% of women with obesity-related anovulatory PCOS versus 18% in the lifestyle-only arm after 32 weeks [1]. Insulin sensitization from GLP-1 receptor agonism adds a second mechanism: lower fasting insulin reduces ovarian androgen synthesis independent of weight change [2].

For men, obesity-driven hypogonadism suppresses testosterone and impairs spermatogenesis. Weight loss with semaglutide raises free testosterone, though no large fertility-endpoint RCT in men has been published yet.

The practical takeaway: GLP-1 therapy may be a bridge to improved fertility rather than an obstacle, provided patients plan the timeline carefully and stop the medication before conception.

When Should You Stop Semaglutide or Tirzepatide Before Trying to Conceive?

Both the Wegovy FDA label and the Zepbound FDA label state that these drugs should be discontinued before a planned pregnancy, with a recommended washout of at least two months for semaglutide [3][4].

The two-month window is based on the drug's pharmacokinetics. Semaglutide has a half-life of approximately seven days, meaning five half-lives (roughly 35 days) are needed to clear approximately 97% of the drug. The FDA chose the two-month washout to add a margin above that minimum. Tirzepatide has a similar half-life of about five days, so its label likewise recommends stopping before conception; the exact recommended interval in the 2024 Zepbound label is two months [4].

Animal reproductive toxicity studies are what drove these warnings. In rats given semaglutide at exposures similar to the clinical dose, investigators observed reduced fetal weight, skeletal malformations, and increased early pregnancy loss [3]. Human teratogenicity data do not yet exist at scale because pregnant women are systematically excluded from GLP-1 trials.

Clinicians should counsel patients that a two-month washout is a minimum, not a target. Given that weight regain often begins within weeks of stopping these drugs, patients and providers should discuss bridging strategies, including continued behavioral support and dietary structure, to preserve fertility-enabling weight loss during the pre-conception window.

Is It Safe to Take GLP-1 Drugs During Pregnancy?

No. Current FDA labeling classifies both semaglutide and tirzepatide as contraindicated in pregnancy based on animal data showing fetal harm [3][4].

A 2024 pharmacovigilance analysis of 83 inadvertent first-trimester semaglutide exposures reported to the FDA Adverse Event Reporting System found a rate of spontaneous abortion consistent with background population rates, but the dataset was too small for definitive conclusions and major malformation outcomes were not fully captured [5]. The Novo Nordisk global pregnancy registry for semaglutide (ongoing, target N=300 exposed pregnancies) will provide more reliable human data, but results are not expected until 2027.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "GLP-1 receptor agonists should be discontinued in women who become pregnant, and prescribers should advise patients planning pregnancy to stop therapy at least two months before conception attempts" [6].

Women who discover an unintended pregnancy while on a GLP-1 agonist should contact their provider immediately. The drug should be stopped at once, and the pregnancy should be monitored with standard-of-care ultrasound. Enrollment in the manufacturer's pregnancy registry is encouraged to contribute to the safety database.

GLP-1 Medications and Oral Contraceptive Reliability

GLP-1 receptor agonists slow gastric emptying, and that delay can reduce peak plasma concentrations of orally administered drugs, including combined oral contraceptives (COCs). This is not a trivial concern: an unintended pregnancy during semaglutide therapy would involve fetal exposure during organogenesis before most women know they are pregnant.

A 2022 pharmacokinetic sub-study of semaglutide 2.4 mg (N=40) found that Cmax of ethinylestradiol was reduced by 22% and norgestimate Cmax by 16% compared with contraceptive-only controls [7]. Whether this reduction crosses the threshold for clinical contraceptive failure is unknown. The 2024 Wegovy label advises that patients using oral contraceptives switch to a non-oral method or add a barrier method for four weeks after each dose escalation [3].

Patients using progestin-only pills, which have a narrower therapeutic window than COCs, should be counseled to switch to a long-acting reversible contraceptive (intrauterine device or subdermal implant) during GLP-1 therapy. Condom use alone is not considered adequate contraception for women on these medications.

How Fast Does Wegovy Work for Weight Loss?

Weight loss with semaglutide 2.4 mg typically begins within the first four weeks, but the full effect builds over 52 to 68 weeks of treatment.

STEP-1 (N=1,961) compared semaglutide 2.4 mg weekly with placebo over 68 weeks in adults with a BMI of 30 or above (or 27 with at least one weight-related comorbidity). Participants assigned to semaglutide lost a mean of 14.9% of body weight versus 2.4% with placebo (difference 12.4 percentage points, P<0.001) [8]. At four weeks, the mean difference in weight loss was approximately 2%, largely from early appetite suppression. By 20 weeks it was roughly 8%, and the curve continued to separate through week 68.

STEP-5, which extended follow-up to 104 weeks (N=304), showed that weight loss was maintained at 15.2% from baseline with continued semaglutide versus 2.6% with placebo, confirming that effects are durable with ongoing therapy [9].

Dose titration is the main rate-limiting step. Wegovy is initiated at 0.25 mg weekly for four weeks, escalated every four weeks through 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg at week 17. Most patients do not reach the full therapeutic dose until month five. Patients should not judge efficacy by early results at sub-therapeutic doses.

Tirzepatide (Zepbound) produces even faster initial separation from placebo. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced a mean weight loss of 20.9% at 72 weeks versus 3.1% placebo (P<0.001) [10]. At week 12, patients on 15 mg had lost approximately 7% of body weight, suggesting a somewhat steeper early trajectory than semaglutide.

Can You Drink Alcohol While Taking Semaglutide or Tirzepatide?

Moderate alcohol consumption is not absolutely prohibited on GLP-1 medications, but it carries specific risks that patients should understand before choosing to drink.

First, alcohol and GLP-1 agonists share overlapping effects on the gastrointestinal tract. Both slow motility and can cause nausea and vomiting. Combining them, especially during the early dose-escalation phase, may worsen these side effects. Patients who already experience nausea on semaglutide often find that even one drink amplifies it substantially.

Second, both alcohol and GLP-1 agonists affect blood glucose. Semaglutide enhances insulin secretion and suppresses glucagon; alcohol independently inhibits hepatic gluconeogenesis. The combination may increase hypoglycemia risk, particularly in patients also taking sulfonylureas or insulin [11]. A 2021 post-marketing analysis of semaglutide in type 2 diabetes found that concomitant alcohol use was associated with a 1.8-fold higher rate of hypoglycemic episodes compared with non-drinkers on the same regimen [11].

Third, for any patient with metabolic dysfunction-associated steatohepatitis (MASH) or elevated liver enzymes, alcohol adds direct hepatotoxic burden to a liver already under stress. The Wegovy FDA label does not list alcohol as a contraindication but does note the hepatotoxicity concern in the context of MASH [3].

The practical guidance from most obesity medicine specialists: limit alcohol to no more than one standard drink per sitting, avoid drinking on an empty stomach, and skip alcohol entirely during the first three months of therapy when GI side effects peak.

Ibuprofen and Semaglutide: Is the Combination Safe?

Ibuprofen and other NSAIDs can be used cautiously with semaglutide, but the interaction profile deserves attention. No pharmacokinetic study has been published specifically on ibuprofen plus semaglutide, but the relevant mechanisms are well understood.

Semaglutide delays gastric emptying. Ibuprofen's gastric safety depends in part on rapid transit through the stomach; prolonged gastric contact increases the local concentration of an ulcerogenic drug on the gastric mucosa. This may raise the risk of gastric irritation, erosions, or peptic ulcer disease in susceptible patients [12]. Patients with a prior history of peptic ulcer disease or who are using low-dose aspirin concurrently should be advised to use acetaminophen as a first-line analgesic instead.

From a pharmacokinetic standpoint, delayed gastric emptying slows ibuprofen absorption, shifting Tmax by 30-45 minutes in studies of other GLP-1 agonists with similar motility effects [13]. Peak analgesic effect will be delayed; patients should not redose early thinking the medication has not worked.

NSAIDs also carry renal risks. Semaglutide reduces caloric intake substantially, and patients eating very little may have lower effective circulating volume, making NSAID-induced renal vasoconstriction more consequential. Clinicians should advise adequate hydration when short-course ibuprofen is used.

GLP-1 Medications After Pregnancy: Breastfeeding Considerations

Semaglutide and tirzepatide are both present in rodent milk, and human lactation data are absent. Given the uncertainty and the potential for GLP-1 receptor agonist effects on the developing neonatal gut, both FDA labels advise against use during breastfeeding [3][4].

The clinical tradeoff is real. Postpartum weight retention is a recognized risk factor for long-term obesity, and some patients have pressing medical reasons (type 2 diabetes, severe obesity) that might argue for restarting therapy soon after delivery. A shared decision-making conversation between patient and clinician should weigh the benefits of maternal weight and glycemic control against the unknown risk of neonatal drug exposure through breast milk.

Women who choose to formula-feed may restart semaglutide or tirzepatide after delivery, though clinicians should confirm that thyroid function and postpartum mood are stable first, as both conditions can confound weight management and are common in the postpartum period.

Male Fertility and GLP-1 Receptor Agonists

Men are rarely included in fertility discussions about GLP-1 therapy, but the question is clinically relevant. Obesity in men is associated with hypogonadotropic hypogonadism, elevated estradiol from peripheral aromatization of androgens in adipose tissue, and reduced sperm motility and morphology.

A 2022 prospective cohort study (N=97 men with obesity and secondary hypogonadism) found that 12 months of semaglutide 1.0 mg weekly, combined with dietary counseling, raised total testosterone from a mean of 9.1 nmol/L to 14.3 nmol/L and improved sperm progressive motility from 28% to 41% [14]. These are clinically meaningful changes, though the study was not powered for live birth outcomes.

No evidence suggests GLP-1 receptor agonists are directly harmful to male reproductive function. Men do not face the same conception-timing restrictions as women, though they should still discuss any planned fertility treatment (IVF, IUI) with their prescribing physician to coordinate care.

Practical Pre-Conception Checklist for Patients on GLP-1 Therapy

Patients planning a pregnancy while on semaglutide or tirzepatide should work through the following steps with their care team:

Set a stop date at least two months before the first unprotected intercourse attempt. Mark the date on a shared calendar with the prescribing clinician.

Transition contraception. If currently using oral contraceptive pills, switch to a non-oral method (IUD, implant) or use a barrier method as backup for four weeks after each dose escalation.

Establish a weight-maintenance plan for the washout window. Registered dietitian referral and behavioral support can blunt the weight regain that commonly follows discontinuation.

Confirm thyroid screening. GLP-1 receptor agonists carry an FDA warning for thyroid C-cell tumors based on rodent data [3]. A baseline TSH should be documented before stopping therapy and rechecked at the start of prenatal care.

Disclose to the obstetric team. The obstetric provider should know the patient was on a GLP-1 agonist and when it was stopped, so appropriate monitoring can be arranged if early pregnancy occurs during or shortly after the washout window.